The global AI for scientific discovery sector is entering a transformative phase as researchers and organizations increasingly use artificial intelligence to process complex datasets, accelerate experimentation, and improve scientific decision-making. Valued at USD 4.80 billion in 2025, the sector is projected to reach USD 5.85 billion in 2026 and approximately USD 34.78 billion by 2035, expanding at an impressive CAGR of 21.90% from 2026 to 2035.
Massive scientific data generation, advances in high-performance computing, cloud infrastructure, and the growing adoption of generative AI for drug discovery are creating powerful opportunities.
Download a Sample Report: https://www.precedenceresearch.com/sample/7938
Compact Scope Table
| Report Coverage | Details |
|---|---|
| 2025 Value | USD 4.80 Billion |
| 2026 Value | USD 5.85 Billion |
| 2035 Value | USD 34.78 Billion |
| CAGR 2026–2035 | 21.90% |
| Leading Region | North America |
| Fastest-Growing Region | Asia Pacific |
| Leading Offering | AI Software Platforms |
| Fastest-Growing Offering | Data Infrastructure and HPC Platforms |
| Leading Technology | Machine Learning Algorithms |
| Fastest-Growing Technology | Generative AI Models |
| Leading Application | Drug Discovery and Biomedical Research |
| Leading End User | Pharmaceutical and Biotechnology Companies |
AI Software Platforms Are Leading Scientific Innovation
AI software platforms accounted for nearly 44% share in 2025, supported by their ability to process large scientific datasets and accelerate research across drug discovery, genomics, chemistry, and materials science.
Machine learning algorithms held the leading technology position with nearly 36% share, helping researchers recognize patterns, predict outcomes, analyze molecular structures, and reduce dependence on repeated physical experimentation.
At the same time, generative AI models are expected to grow at the fastest pace as they can generate molecular structures, simulate scientific scenarios, and support the development of new hypotheses.
Generative AI Is Accelerating Drug Discovery
Drug discovery and biomedical research represented nearly 34% share in 2025. Pharmaceutical and biotechnology companies are increasingly adopting AI to analyze biological datasets, predict drug-target interactions, optimize clinical research, and identify promising candidates.
Generative AI is creating an additional opportunity by supporting virtual molecule design and computational experimentation. Platforms such as Merck’s ADDISON demonstrate how AI can contribute to faster molecular discovery and research workflows.
HPC and Cloud Infrastructure Are Becoming Essential
As scientific AI models become more sophisticated, demand for powerful computing infrastructure is increasing.
Data infrastructure and high-performance computing platforms are expected to record the fastest growth among offerings. These platforms provide the processing power, storage, networking, and scalability required to train large AI models and analyze high-volume scientific datasets.
Cloud-based HPC environments are also allowing researchers to access scalable computing resources without making the full capital investment associated with maintaining dedicated infrastructure.
Materials Science Is Emerging as a High-Growth Opportunity
Materials science and chemistry discovery is expected to experience rapid growth as researchers use AI to predict material properties and simulate atomic-level interactions before physical synthesis.
Graph neural networks, deep learning, and physics-informed models can help accelerate the development of advanced materials while reducing experimental costs and research timelines.
This is particularly relevant for chemical and materials companies seeking more efficient ways to discover sustainable materials and optimize production processes.
North America Leads While Asia Pacific Accelerates
North America accounted for nearly 40% of the global share in 2025, supported by advanced AI capabilities, strong research infrastructure, pharmaceutical innovation, and the presence of major technology companies.
The North American sector is projected to grow from USD 1.92 billion in 2025 to approximately USD 14.09 billion by 2035, advancing at a 22.06% CAGR.
The U.S. remains a major innovation center, supported by federal research organizations, technology companies, universities, and large private-sector investments.
Asia Pacific is expected to record the fastest growth as governments and industries increase investment in AI-enabled research across pharmaceuticals, biotechnology, chemicals, materials science, defense, and advanced manufacturing.
Companies Are Competing Through AI and Scientific Innovation
The competitive landscape includes technology companies, AI specialists, pharmaceutical organizations, and scientific software providers.
Major participants include NVIDIA, Google, IBM, Microsoft, Amazon Web Services, Schrödinger, Recursion Pharmaceuticals, Insilico Medicine, BenevolentAI, Atomwise, AbCellera Biologics, Novartis, Benchling, BenchSci, Generate Biomedicines, and Healx.
Recent developments highlight the rapid evolution of the sector. In February 2026, Tamarind Bio secured USD 13.6 million in Series A funding to expand access to AI models for life science researchers. Google DeepMind also announced a national partnership in India in February 2026 to broaden researchers’ access to AI tools including AI Co-Scientist, Earth AI, and AlphaGenome.
The Road Ahead
The future of AI for scientific discovery will be shaped by generative AI, multimodal models, high-performance computing, cloud infrastructure, automated experimentation, and increasingly integrated scientific datasets.
With the sector projected to reach USD 34.78 billion by 2035, AI is moving beyond assisting researchers and toward becoming a core engine for discovery across pharmaceuticals, biotechnology, chemistry, materials science, climate research, physics, and other scientific disciplines.
The biggest opportunity will lie in combining AI intelligence with high-quality scientific data, powerful computing, and human research expertise to accelerate breakthroughs that would take far longer through traditional approaches.
Buy this report: https://www.precedenceresearch.com/checkout/7938
About Us
Healthcare Prism is a dedicated healthcare insights and outreach platform, operating as an extension of Precedence Research. We share relevant perspectives, industry developments, emerging trends, and research-driven insights across the global healthcare sector. Our content is built on the knowledge, research standards, and expertise of Precedence Research, with a focus on making healthcare information clear, accessible, and useful for industry professionals, businesses, researchers, and healthcare stakeholders. Healthcare Prism serves as a focused platform to extend the reach of Precedence Research’s healthcare insights and connect them with a broader professional audience.
You can place an order or ask any questions, please feel free to contact us at [email protected]
Quick Contact:
Europe Region: +44 778 256 0738
North America Region: +1 8044 4193 44
APAC Region: +91 9356 9282 04 and +65 31065601
Visit Our Website: Precedence Research – Advisory, Research & Reports